LUNG NON-SMALL CELL CARCINOMA

This large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to a highly targeted form of radiation therapy works better than radiation alone. It is for people with early-stage, non-small cell lung cancer who cannot have surgery. The main goal is to…

This large, late-stage trial is testing if adding a new oral drug (AZD6738) to an existing immunotherapy (durvalumab) works better than the immunotherapy alone to keep non-small cell lung cancer from coming back. It is for patients who have already had chemotherapy and surgery to…

This study is testing whether combining a cancer vaccine (CIMAvax) with immunotherapy drugs (nivolumab or pembrolizumab) is safe and effective for people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to help the body's immune system better…

This study is testing a two-part treatment for patients with stage II or III non-small cell lung cancer who are not candidates for surgery or standard chemo-radiation. First, patients receive a shorter, more intense course of radiation over three weeks. Then, they receive an immu…

This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…

This study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …

This study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…

This study compares two drugs, infliximab and vedolizumab, to treat severe colon inflammation and diarrhea caused by cancer immunotherapy drugs. The trial involves 47 patients with melanoma, lung cancer, or urinary cancers who developed these side effects. Researchers aim to find…

This study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…

This early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…

This study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…

This study is for people with stage IV non-small cell lung cancer. It tests if adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps patients live longer than immunotherapy alone. The trial enrolled 339 patients who had not progressed after a…

This early-stage study is testing whether two immunotherapy drugs (ipilimumab and nivolumab) can be safely combined with radiation therapy for patients with stage II or III non-small cell lung cancer. The goal is to see if this combination helps the immune system attack the cance…

This early-stage study is testing whether adding a drug called papaverine to a precise form of radiation therapy makes the treatment more effective for patients with non-small cell lung cancer or lung tumors that have spread. The main goal is to find the safest dose of papaverine…

This study is testing an experimental pill called AMG 510 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The pill is designed to block this specific mutation, which can drive cancer growth, in patients whose cancer has wor…

This study is testing whether the immunotherapy drug pembrolizumab can prevent lung cancer in people at high risk. It includes people with suspicious lung nodules that haven't grown or shrunk, and people who've had early-stage lung cancer treated before. Participants receive the …

This study is testing whether a drug called anamorelin can improve appetite and help stop weight loss in people with advanced non-small cell lung cancer. Participants will take either the drug or a placebo pill daily for nine weeks. Researchers will interview patients about their…

This study is testing a simple conversation tool designed to help people with lung cancer better understand their treatment options and participate in decisions with their doctors. The tool is being evaluated at two cancer centers with 98 participants who have non-small cell lung…

This study is testing a telehealth program designed to help people who have finished treatment for early-stage lung or colorectal cancer. It compares a special coaching program that teaches self-management skills to standard educational materials. The goal is to see if the coachi…

This study aims to find early signs of heart damage in cancer patients receiving radiation therapy to the chest. Researchers will use special heart scans and blood tests on 28 participants before, during, and after their radiation treatment. The goal is to learn how to identify p…

This study aims to create a tool to predict which cancer patients are most likely to develop nerve damage (like tingling or numbness in hands and feet) from a common class of chemotherapy drugs called taxanes. Researchers will follow over 1,300 patients with breast, lung, or ovar…